wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 11. no 2. June 2006  
 TABLE OF CONTENT

 Bronchial asthma
Xolair in clinical practice
Barbara Rogala, Alicja Kasperska-Zając

Monoclonal anti-IgE antibody, omalizumab (Xolair, Novartis Pharma AG) as an add-on to current therapy of moderate-to-severe persistent asthma significantly alleviated the symptoms of the disease, enabled better disease control, improved quality of life, reduced rescue medication doses, exerted steroid-sparing effect. Omalizumab should be considered in patients with severe and persistent asthma who continue to show symptoms of inadequately controlled asthma despite optimal therapy.


keywords: omalizumab, astma, nieżyt nosa, omalizumab, asthma, allergic rhinitis

pages: from 83 to 86



estimated time of download (74 kB)
broadband speed:561282565121024[kbps]
time:166322[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.